Special Poster Feature: Certolizumab Pegol: A Future Treatment Option for Patients Suffering from Psoriasis

This is a summary of the data presented by UCB on 13th–17th September 2017 at the 26th European Academy of Dermatology and Venereology (EADV) congress 2017 in Geneva, Switzerland

Disclosure: Cimzia® clinical data for the treatment of psoriasis and the clinical data relevant to the treatment of women of childbearing age have been submitted to regulatory authorities and are pending approval.
Acknowledgements: Prof Alexa B. Kimball, CEO and President at Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Inc., Boston, Massachusetts, USA, presented the data from references 10 and 14 at the 26th European Academy of Dermatology and Venereology (EADV) congress as oral and free presentations, respectively. Writing assistance was provided by Afsaneh Khetrapal, ApotheCom, London, UK.
Support: The publication of this article was funded by UCB Biopharma.
Citation: EMJ Dermatol. 2017;5[1]:64-65.

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Download (PDF, 62KB)

Comments are closed.